Article
Safety and effectiveness of recombinant factor XIII‐A2 in congenital factor XIII deficiency: Real‐world evidence
1 Feb 2022
Abstract excerpt
Background Regular factor XIII (FXIII) prophylaxis is standard treatment for congenital FXIII A-subunit deficiency (FXIII-A CD). Recombinant factor XIII-A2 (rFXIII-A2) was extensively evaluated in the mentor trials. Objective To assess real-world safety and treatment effectiveness of rFXIII-A2 prophylaxis from the mentor 6 trial. Patients/Methods mentor 6 was a noninterventional, postauthorization safety study...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
